Precigen, Inc. (PGEN) Stock Score, Valuation & Financial Research
Precigen, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 13/100.
Quick answer for PGEN
Precigen, Inc. currently has a Wall Street Score of 13/100. The stored market price is $6.85. Its financial score is 12/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Precigen, Inc. does
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provide
PGEN financial snapshot
- Wall Street Score:
- 13/100
- Current price:
- $6.85
- Market capitalization:
- $2.44B
- Revenue:
- $31.6M
- Net income:
- $-204.4M
- Free cash flow:
- $-89.8M
- Cash:
- $7.5M
- Total debt:
- $98.3M
- EPS:
- -1.41
- Financial score:
- 12/100
- Valuation score:
- 0/100
- Revenue score:
- 40/100
What stands out
- Reported year-over-year revenue growth is +2.3%.
- Free cash flow is $-89.8M, showing cash burn in the current stored period.
- The balance sheet shows $7.5M of cash versus $98.3M of total debt, so leverage deserves attention.
- The current research record carries a high debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research PGEN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.